GlassScriptPhysician profile
Ying Zhuo
NPI 1043491293
$43,039.44
in general payments reported to CMS, 2019-2025
28 companies · $6,075 in 2025
The $6,075 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,562 · 2020: $1,636 · 2021: $5,706 · 2022: $9,125 · 2023: $9,182 · 2024: $3,752 · 2025: $6,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,671.25 |
| Food and Beverage | $338.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15,875.28 | 2019-2024 | Lynparza |
| Pfizer INC. | $7,672.18 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $6,520.00 | 2023 | Xpovio |
| Daiichi Sankyo INC. | $5,367.87 | 2022-2025 | Enhertu |
| Genentech USA, INC. | $1,825.28 | 2019-2024 | Venclexta |
| Janssen Scientific Affairs, LLC | $1,775.75 | 2022-2023 | Imbruvica |
| Incyte Corporation | $1,650.00 | 2025 | |
| Genentech, INC. | $1,556.74 | 2022-2024 | Venclexta, Tecentriq, Polivy |
| Foundation Medicine, INC. | $147.52 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $120.55 | 2019-2023 | Opdualag, Opdivo |
| Lilly USA, LLC | $105.30 | 2022 | |
| Janssen Biotech, INC. | $100.05 | 2019 | |
| Ge Healthcare | $63.84 | 2022 | |
| Merck Sharp & Dohme LLC | $48.36 | 2019 | |
| Celgene Corporation | $40.72 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $40.54 | 2019-2024 | Libtayo |
| Amgen INC. | $40.50 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $19.94 | 2019 | |
| Kite Pharma, INC. | $15.86 | 2020 | |
| Abbvie INC. | $15.15 | 2019 | |
| Seagen INC. | $13.67 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $12.42 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying Zhuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.